Fate Therapeutics, Inc. (FATE) analyst actions
Rating and price-target actions on FATE in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the FATE overview →
2 measured FATE analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | Press release | -2.33% | -0.39% | |
| Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors | Press release | -3.68% | +8.42% |
Keep exploring
More FATE: earnings → · SEC filings → · FATE overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Accuray Incorporated (ARAY) | 288 | 0.00% | 51% |
| Chemed Corp (CHE) | 288 | +0.02% | 53% |
| RenovaCare, Inc. (RCAR) | 286 | 0.00% | 41% |
| Cellectis S.A. - American Depositary Shares (CLLS) | 285 | -0.01% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.